Abstract
167P - Utilization and outcomes of Eribulin Mesylate POst a cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i): An observational real-World study in UnitEd States community oncology pRactices (EMPOWER)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have